{"Clinical Trial ID": "NCT00274469", "Intervention": ["INTERVENTION 1:", "Fulvestant 500 mg", "Fulvestant 500 mg", "INTERVENTION 2:", "Anastrozole 1 mg", "Anastrozole 1 mg"], "Eligibility": ["Incorporation criteria:", "Positive confirmed hormone receptor advanced breast cancer, menopausal women", "- Exclusion criteria:", "Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed)."], "Results": ["Performance measures:", "Rates of clinical benefits", "A clinical benefit sponsor (CB) is defined as a patient with the best overall response of complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks assessed according to modified RECIST. The clinical benefit rate is the percentage of patients with CB.", "Timeline: From randomization to cut-off data (DCO) for primary analysis. The first and last patients were enrolled on February 6, 2006 and July 11, 2007, respectively. The DCO for primary analysis was on January 10, 2008, 6 months after the last patient was enrolled.", "Results 1:", "Title of the arm/group: Fulvestant 500 mg", "Description of the arm/group: Fulvestant 500 mg", "Total number of participants analysed: 102", "Type of measurement: Number", "Unit of measure: Percentage of participants 72.5", "Results 2:", "Title of arm/group: Anastrozole 1 mg", "Description of the arm/group: Anastrozole 1 mg", "Total number of participants analysed: 103", "Type of measurement: Number", "Unit of measure: percentage of participants 67.0"], "Adverse Events": ["Undesirable Events 1:", "Total: 24/101 (23.76 per cent)", "LYMPHADENOPATHY 0/101 (0.00 %)", "NEUTROPENIA FEBRILE 20/101 (0.00 %)", "Atmosphere FIBRILLATION 1/101 (0.99%)", "ARPHYTHMIA 20/101 (0.00 %)", "CARDIAC FAITH 22/101 (1.98 per cent)", "- CARDIAC FEATURED REGISTRATION 20/101 (0.00 %)", "- CORONARY OSTICAL STENOSES 20/101 (0.00 %)", "LABRICAL DESORDOR 0/101 (0.00 %)", "BLINDSS 21/101 (0.99%)", "UCRE GASTRIC 1/101 (0.99%)", "NAUSEA 1/101 (0.99%)", "Adverse Events 2:", "Total: 22/103 (21.36%)", "LYMPHADENOPATHY 1/103 (0.97%)", "NEUTROPENIA FEBRILE 21/103 (0.97%)", "Atmosphere FIBRILLATION 1/103 (0.97%)", "ARRHYTHMIA 21/103 (0.97%)", "CARDIAC FAITH 20/103 (0.00 per cent)", "THE CARDIAC FAITH 21/103 (0.97%)", "CORONARY OSIAL STENOSIS 21/103 (0.97%)", "1/103 (0.97%)", "BLINDSS 20/103 (0.00 %)", "GASTRIC CER 0/103 (0.00 %)", "- NAUSEA 0/103 (0.00 %)"]}